Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (07 / 03 / 2014)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

    Polycythemia Vera

    Recommended Related to Leukemia & Lymphoma

    B-Cell Acute Lymphoblastic Leukemia in Children

    Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. It affects certain cells in the immune system, called B cells and T cells. ALL usually affects B cells in children. It's natural to feel worried when you learn your child has acute lymphoblastic leukemia, but keep in mind that almost all children can be cured of this disease. B-cell ALL makes your child more likely to get infections, because he doesn't have the protection of those B cells. The disease starts...

    Read the B-Cell Acute Lymphoblastic Leukemia in Children article > >

    Added Quintás-Cardama et al. as reference 21.

    Primary Myelofibrosis

    Added text to state that about 60% of patients with primary myelofibrosis carry a JAK2 mutation, and about 5% to 10% of the patients have activating mutations in the thrombopoietin receptor gene, MPL. Also added that almost 90% of the patients without JAK2 or MPL carry a somatic mutation of the calreticulin gene, which is associated with a more indolent clinical course than is seen with JAK2 or MPL mutations (cited Klampfl et al. and Nangalia et al. as references 6 and 7, respectively).

    Essential Thrombocythemia

    Added text to state that about 60% of patients with primary myelofibrosis carry a JAK2 mutation, and about 5% to 10% of the patients have activating mutations in the thrombopoietin receptor gene, MPL. Also added that almost 90% of the patients without JAK2 or MPL carry a somatic mutation of the calreticulin gene, which is associated with a more indolent clinical course than is seen with JAK2 or MPL mutations (cited Klampfl et al. and Nangalia et al. as references 7 and 8, respectively).

    Added Quintás-Cardama et al. as reference 23.

    This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

    WebMD Public Information from the National Cancer Institute

    Last Updated: May 28, 2015
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    1
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
     
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article